Cho KR - Search Results

1

Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.

Lazo de la Vega L, Samaha MC, Hu K, Bick NR, Siddiqui J, Hovelson DH, Liu CJ, Carter CS, Cho KR, Sciallis AP, Tomlins SA. Lazo de la Vega L, et al. Among authors: cho kr. Mol Cancer Res. 2019 Mar;17(3):731-740. doi: 10.1158/1541-7786.MCR-18-1178. Epub 2019 Jan 4. Mol Cancer Res. 2019. PMID: 30610106

2

Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.

Wu R, Zhai Y, Fearon ER, Cho KR. Wu R, et al. Among authors: cho kr. Cancer Res. 2001 Nov 15;61(22):8247-55. Cancer Res. 2001. PMID: 11719457

3

Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.

Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR. Schwartz DR, et al. Among authors: cho kr. Cancer Res. 2003 Jun 1;63(11):2913-22. Cancer Res. 2003. PMID: 12782598

4

Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.

Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Hendrix ND, et al. Among authors: cho kr. Cancer Res. 2006 Feb 1;66(3):1354-62. doi: 10.1158/0008-5472.CAN-05-3694. Cancer Res. 2006. PMID: 16452189

5

Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR. Wu R, et al. Among authors: cho kr. Cancer Cell. 2007 Apr;11(4):321-33. doi: 10.1016/j.ccr.2007.02.016. Cancer Cell. 2007. PMID: 17418409 Free article.

6

Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion.

Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, Cho KR. Zhai Y, et al. Among authors: cho kr. Cancer Res. 2007 Nov 1;67(21):10163-72. doi: 10.1158/0008-5472.CAN-07-2056. Cancer Res. 2007. PMID: 17974957

7

Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.

Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Wu R, et al. Among authors: cho kr. Clin Cancer Res. 2011 Dec 1;17(23):7359-72. doi: 10.1158/1078-0432.CCR-11-1388. Epub 2011 Sep 8. Clin Cancer Res. 2011. PMID: 21903772 Free PMC article.

8

Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Wu R, et al. Among authors: cho kr. Am J Pathol. 2013 Apr;182(4):1391-9. doi: 10.1016/j.ajpath.2012.12.031. Am J Pathol. 2013. PMID: 23499052 Free PMC article.

9

HRAS mutations are frequent in inverted urothelial neoplasms.

McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R. McDaniel AS, et al. Among authors: cho kr. Hum Pathol. 2014 Sep;45(9):1957-65. doi: 10.1016/j.humpath.2014.06.003. Epub 2014 Jun 18. Hum Pathol. 2014. PMID: 25097040 Free PMC article.

10

Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.

McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, Cho KR. McDaniel AS, et al. Among authors: cho kr. JAMA Oncol. 2015 Nov;1(8):1128-32. doi: 10.1001/jamaoncol.2015.1618. JAMA Oncol. 2015. PMID: 26181193 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page